SpringWorks Therapeutics, Inc. reported a loss of $83.2 million, or $1.11 per share, for the first quarter of 2025. The company posted total revenue of $49.1 million for the period.
OGSIVEO generated $44.1 million in net product revenue during Q1 2025, while GOMEKLI, recently approved, contributed $4.9 million in net product revenue. Total revenue of $49.087 million in Q1 2025 represents a significant increase from $21.006 million in Q1 2024.
While the reported loss and revenue fell short of average analyst estimates, the substantial year-over-year revenue growth demonstrates the commercial momentum from the launch of both OGSIVEO and GOMEKLI. This indicates continued progress in establishing its precision medicine portfolio in the market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.